On September 27, 2018 INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, reported that Saeed Motahari, president and chief executive officer, and Andy Long, chief financial officer, will present at the upcoming 2018 Cantor Global Healthcare Conference as follows (Press release, Insys Therapeutics, SEP 27, 2018, View Source [SID1234529647]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, Oct. 2, 2018
Time: 1:05 p.m. Eastern Time
Location: New York, N.Y.
The presentation will be webcast live at the aforementioned time, and archived for 90 days thereafter, via the Investors section of company’s website at View Source, under Presentations & Events. Accessible at the same webpage, the presentation slides will be available during and after the conference.

On September 27, 2018 Dynavax Technologies Corporation (NASDAQ:DVAX) reported that Eddie Gray, Dynavax’s Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018 at 10:40 AM ET at the InterContinental New York Barclay Hotel (Press release, Dynavax Technologies, SEP 27, 2018, View Source [SID1234530121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and replayed versions of the webcast will be available on the "Events and Presentations" section of the Dynavax website at View Source

On September 26, 2018 Novavax, Inc. (NASDAQ: NVAX) reported that it will present at the Ladenburg Thalmann 2018 Healthcare Conference and the Cantor Global Healthcare Conference 2018, both in the first week of October (Press release, Novavax, SEP 26, 2018, View Source [SID1234529628]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference details are as follows:

Ladenburg Thalmann 2018 Healthcare Conference

Date and Time: Tuesday, October 2, 12:00 p.m. – 12:25 p.m.
Location: Track 5, Montmartre, Sofitel New York
Live webcast: www.novavax.com, "Investors"/"Events"

Cantor Global Healthcare Conference 2018

Date and Time: Wednesday, October 3, 10:55 a.m. – 11:25 p.m.
Location: Track 2, Empire Ballroom 1, InterContinental New York Barclay Hotel
Live webcast: www.novavax.com, "Investors"/"Events"

On September 26, 2018 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:10 a.m. ET at the InterContinental New York Barclay Hotel (Press release, Syndax, SEP 26, 2018, View Source [SID1234529598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the Company’s presentation can be accessed from the Investor section of the Company’s website at www.syndax.com, where a replay of the events will also be available for a limited time.

On September 26, 2018 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported that Troy Wilson, Ph.D., J.D., Kura’s President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York on Wednesday, October 3, 2018 at 3:00 p.m. ET / 12:00 p.m. PT (Press release, Kura Oncology, SEP 26, 2018, View Source [SID1234529614]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.